Affiliations: [a] Faculty of Medicine, Kunming University of Science and Technology, Kunming, Yunnan, China | [b] State Key Laboratory of Molecular Oncology, Cancer Institute (Hospital), Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
Correspondence:
[*]
Corresponding authors: Zhi-Zhou Shi, Faculty of Medicine, Kunming University of Science and
Technology, No.727 South Jingming Road, Kunming 650500, Yunnan, China, Tel.: +86 13529427683; E-mail: zhizhoushi@126.com;
Jia-Jie Hao, State Key Laboratory of Molecular Oncology, Cancer Institute
(Hospital), Peking Union Medical College and Chinese Academy of Medical
Sciences, 17 Panjiayuan South lane, Beijing 100021, China. Tel.: +86 10 87788425; E-mail: hjj8173@126.com
Abstract:
BACKGROUND: At present no objective prognostic biomarkers have been
established in esophageal squamous cell carcinoma (ESCC). OBJECTIVE: To identify the genomic biomarkers associated with
clinicopathological factors and prognosis of ESCCs. METHODS: Real-time PCR was used to analyze the copy number change
and mRNA expression of genes. The survival curves were plotted according to
Kaplan-Meier method and checked by log-rank test. RESULTS: We revealed the copy number increase of CACNA1C (12p13.33)
and MRPL21 (11q13.2) as well as decrease of VIPR2 (7q36.3) and MAP3K7 (6q15)
in ESCC by Real-time PCR, and also found that MRPL21 was significantly
overexpressed and VIPR2 was underexpressed in ESCC. Gain of CACNA1C was
significantly associated with differentiation (P = 0.043), and loss of VIPR2
was significantly linked with good prognosis (P = 0.016). Most importantly,
we revealed that loss of MAP3K7 was significantly correlated with good
prognosis in ESCC patients (n = 159, P = 0.004), especially in Grade II and
pN0 patients (n = 76, P = 0.005 and n = 74, P = 0.024). Multivariate analysis
confirmed that MAP3K7 loss provided prognostic information in ESCC (HR, 0.454; 95% CI: 0.208-0.995; P = 0.048). CONCLUSIONS: Loss of MAP3K7 may be a candidate prognostic factor in
ESCC.
